Neurology Minute

Dr. Vikram Karnak discusses the novel hereditary ataxia SCA27b, its genetic basis, symptoms, and potential treatments, emphasizing the need for testing in unexplained adult-onset ataxia.

In part two of this two-part series, Dr. Justin Abbatemarco and Dr. Maarten Titulaer discuss the link between HSV and NMDAR encephalitis and how that impacts longitudinal recovery. Show reference:  https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000210109

In part one of this two-part series, Dr. Justin Abbatemarco and Dr. Maarten Titulaer discuss long-term cognitive and functional outcomes in patients with anti-NMDAR encephalitis and their implications for rehabilitation. Show reference: https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000210109

In part two of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss abandoning the term lupus myelitis and emphasize the importance of accurately naming and identifying each autoimmune condition. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329  

In part one of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss key features of inflammatory myelopathy in rheumatologic disease, helping to better characterize the underlying causes of lupus myelitis. Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329 

Dr. Tesha Monteith discusses the Brain & Life article, “Could GLP-1 Receptor Agonists Reduce the Risk of Neurologic Disorders?” by Hallie Levine, available in the latest issue of Brain & Life or at brainandlife.org.  Show reference: https://www.brainandlife.org/articles/new-weight-loss-drugs-may-help-neurologic-disorders 

In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how to differentiate between CAA-RI and PACNS. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

Dr. Gregg Day and Dr. Kathryn T. Hall discuss the complexities of the placebo effect, its variability among patients, and the genetic factors that influence responses to placebo treatments. 

In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss the underlying pathophysiology and how to diagnose primary angiitis of the CNS in clinical practice. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how cerebral amyloid angiopathy and CAA-RI present in clinical practice and how to make a diagnosis. Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

Dr. Stacey Clardy discusses vitamin D in this lab minute.

Dr. Halley Alexander discusses the Neurology Today article, "Could Reducing Environmental Toxins Help Mitigate the Risk for Parkinson’s Disease? Where the Evidence Is Leading" by Gina Shaw, available in the November 7th issue of Neurology Today or at neurologytoday.com. Show reference: https://journals.lww.com/neurotodayonline/pages/articleviewer.aspx?year=2024&issue=11070&article=00001&type=Fulltext

In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Jennifer L. Orthmann Murphy highlight important indicators for when to suspect hereditary spastic paraplegia, as well as guidelines for testing and interpreting results.  Show references: https://www.neurology.org/doi/10.1212/NXG.0000000000200192  https://cshperspectives.cshlp.org/content/early/2024/08/10/cshperspect.a041457

In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Jennifer L. Orthmann Murphy discuss practical approaches to genetic adrenoleukodystrophy. Show references: https://www.neurology.org/doi/10.1212/NXG.0000000000200192  

In the first part of this three-part series, Dr. Justin Abbatemarco and Dr. Jennifer L. Orthmann Murphy discuss red flag symptoms that suggest the need for genetic testing in patients with white matter disease. Show references: https://www.neurology.org/doi/10.1212/NXG.0000000000200192 https://cshperspectives.cshlp.org/content/early/2024/08/10/cshperspect.a041457

Dr. Rae Bacharach discusses the Neurology Today article, “Early Treatment Cuts Relapse Risk in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease,” by Gina Shaw, available in the latest issue of Neurology Today or at neurologytoday.com.  Show reference: https://journals.lww.com/neurotodayonline/pages/default.aspx https://jamanetwork.com/journals/jamaneurology/article-abstract/2822964 

In the final part of this three-part series, Drs. Tesha Monteith, Messoud Ashina, and Andrea Cipriani discuss what you need to know about analyzing network meta-analysis. Show reference: https://www.bmj.com/content/386/bmj-2024-080107  

Drs. Justin Abbatemarco, Marius Ringelstein, and Ilya Ayzenberg discuss a new class of complement inhibitors that we're using in NMOSD. Show reference: https://www.neurology.org/doi/full/10.1212/WNL.0000000000209888

In part two of this three-part series, Drs. Tesha Monteith, Messoud Ashina, and Andrea Cipriani discuss clinical pearls on how to select an acute treatment plan for migraine. Show reference: https://www.bmj.com/content/386/bmj-2024-080107 

In the first part of this three-part series, Drs. Tesha Monteith, Messoud Ashina, and Andrea Cipriani explain the significance of this study and how its findings can be applied in clinical practice. Show reference: https://www.bmj.com/content/386/bmj-2024-080107